Literature DB >> 26210744

A UHPLC-TOF/MS method based metabonomic study of total ginsenosides effects on Alzheimer disease mouse model.

Yingge Gong1, Ying Liu1, Ling Zhou1, Xin Di2, Wei Li1, Qing Li1, Kaishun Bi3.   

Abstract

A metabonomic method was established to find potential biomarkers and study the metabolism disturbance in Alzheimer disease animal model. Total ginsenosides, as potential agent in neuroprotection and anti-inflammation, was also studied to learn the regulation mechanism to plasma metabolites in model animals. In experiment, amyloid beta 1-42 was occupied to form Alzheimer disease animal model. After drug administration, animals were evaluated by Morris water maze behavior test and sacrificed. Plasma samples were then analyzed using UHPLC-TOF/MS method to determine the endogenous metabolites. Behavior test results revealed that the spatial learning and memory abilities were deficit in model mice, and total ginsenosides could improve cognition abilities in dose-dependent manners. Principal component analysis showed that model and sham were divided into two groups, which means the metabolic network of mice was disturbed after modeling. Accordingly, 19 biomarkers were found and identified. In model group, the levels of proline, valine, tryptophan, LPC (14:0), LPC (15:0), LPC (15:1), LPC (17:0), LPC (18:2), LPC (18:3) and LPC (20:4) were up-regulated, while the levels of acetylcarnitine, palmitoylcarnitine, vaccenylcarnitine, phytosphingosine, N-eicosanoylethanolamine, hexadecenoic acid, docosahexaenoic acid, docosapentaenoic acid and octadecadienoic acid were down-regulated. The levels of these metabolites were recovered in different degrees after total ginsenosides administration. Combining with behavior study results, total ginsenosides could ameliorate both cognition symptoms and metabolic changes in model animals. This metabonomic approach provided a feasible way to understand the endogenous alterations of AD and to study the pharmacodynamic activity of novel agents.
Copyright © 2015 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Alzheimer disease; Animal model; Biomarkers; Metabonomics; Total ginsenosides

Mesh:

Substances:

Year:  2015        PMID: 26210744     DOI: 10.1016/j.jpba.2015.07.007

Source DB:  PubMed          Journal:  J Pharm Biomed Anal        ISSN: 0731-7085            Impact factor:   3.935


  6 in total

1.  Schisandrin ameliorates cognitive impairment and attenuates Aβ deposition in APP/PS1 transgenic mice: involvement of adjusting neurotransmitters and their metabolite changes in the brain.

Authors:  Bin-Bin Wei; Ming-Yan Liu; Zai-Xing Chen; Min-Jie Wei
Journal:  Acta Pharmacol Sin       Date:  2018-01-11       Impact factor: 6.150

2.  An elaborative NMR based plasma metabolomics study revealed metabolic derangements in patients with mild cognitive impairment: a study on north Indian population.

Authors:  Umesh Kumar; Abhai Kumar; Smita Singh; Payal Arya; Sandeep Kumar Singh; Rameshwar Nath Chaurasia; Anup Singh; Dinesh Kumar
Journal:  Metab Brain Dis       Date:  2021-03-02       Impact factor: 3.584

3.  Blood-based metabolic signatures in Alzheimer's disease.

Authors:  Francisca A de Leeuw; Carel F W Peeters; Maartje I Kester; Amy C Harms; Eduard A Struys; Thomas Hankemeier; Herman W T van Vlijmen; Sven J van der Lee; Cornelia M van Duijn; Philip Scheltens; Ayşe Demirkan; Mark A van de Wiel; Wiesje M van der Flier; Charlotte E Teunissen
Journal:  Alzheimers Dement (Amst)       Date:  2017-09-06

4.  Metabolic profiling reveals dysregulated lipid metabolism and potential biomarkers associated with the development and progression of Fragile X-Associated Tremor/Ataxia Syndrome (FXTAS).

Authors:  Marwa Zafarullah; Grzegorz Palczewski; Susan M Rivera; David R Hessl; Flora Tassone
Journal:  FASEB J       Date:  2020-11-01       Impact factor: 5.191

5.  Metabonomics Study in Mice With Learning and Memory Impairment on the Intervention of Essential Oil Extracted From Cinnamomum camphora Chvar. Borneol.

Authors:  Yin Tang; Xiaofan Lv; Yumin Liu; Donghong Cui; Yani Wu
Journal:  Front Pharmacol       Date:  2022-03-10       Impact factor: 5.810

6.  Yuan-Zhi decoction in the treatment of Alzheimer's disease: An integrated approach based on chemical profiling, network pharmacology, molecular docking and experimental evaluation.

Authors:  Qiong Wu; Xiang Li; Xiao-Wen Jiang; Dong Yao; Li-Jun Zhou; Zi-Hua Xu; Nan Wang; Qing-Chun Zhao; Zhou Zhang
Journal:  Front Pharmacol       Date:  2022-08-24       Impact factor: 5.988

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.